GlassScriptPhysician profile
Kenneth Hershon
NPI 1255391017
$35,230.47
in general payments reported to CMS, 2019-2025
32 companies · $93.40 in 2025
The $93.40 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $6,543 · 2021: $3,097 · 2023: $342 · 2024: $352 · 2025: $93.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.89 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21,019.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $5,566.41 | 2019-2024 | Repatha, Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $4,344.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $2,527.77 | 2019 | |
| Abbvie INC. | $304.54 | 2019-2025 | |
| Lilly USA, LLC | $192.70 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Nevro Corp. | $185.30 | 2021 | |
| Medtronic Minimed, INC. | $164.93 | 2019 | |
| Mannkind Corporation | $129.85 | 2019-2023 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $109.68 | 2019 | |
| Xeris Pharmaceuticals, INC. | $107.13 | 2020-2024 | Recorlev, Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $81.85 | 2023-2025 | |
| Abbott Laboratories | $78.67 | 2020-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $48.37 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $45.02 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.74 | 2019-2020 | |
| Amarin Pharma, INC. | $36.36 | 2019-2020 | |
| Antares Pharma, INC. | $35.87 | 2019-2024 | Xyosted |
| Regeneron Healthcare Solutions, INC. | $32.91 | 2019 | |
| Medtronic, INC. | $22.35 | 2023 | Minimed 780g |
| Radius Health, INC. | $21.16 | 2020 | |
| Esperion Therapeutics, INC. | $16.93 | 2023 | Nexletol |
| Valeritas, INC. | $16.62 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.49 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.27 | 2019 | |
| Lifescan, INC. | $16.18 | 2020 | |
| Astellas Pharma US INC | $15.27 | 2023 | Veozah |
| Averitas Pharma INC. | $13.61 | 2023 | Qutenza |
| Insulet Corporation | $13.36 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.00 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Hershon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.